Helen of Troy Limited (HELE) 10-Q 8 Oct 21 2022 Q2 Quarterly report Financial data

Cover page

Cover page - shares	6 Months Ended
	Aug. 31, 2021	Sep. 30, 2021
Entity Addresses [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Aug. 31, 2021
Document Transition Report	false
Entity File Number	001-14669
Entity Registrant Name	HELEN OF TROY LIMITED
Entity Incorporation, State or Country Code	D0
Entity Tax Identification Number	74-2692550
Entity Address, Address Line One	1 Helen of Troy Plaza
Entity Address, City or Town	El Paso
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	79912
City Area Code	915
Local Phone Number	225-8000
Title of 12(b) Security	Common Shares, $0.10 par value per share
Trading Symbol	HELE
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,127,575
Entity Central Index Key	0000916789
Current Fiscal Year End Date	--02-28
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false
Other Address
Entity Addresses [Line Items]
Entity Address, Address Line One	Clarendon House, 2 Church Street
Entity Address, City or Town	Hamilton
Entity Address, Country	BM

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Aug. 31, 2021	Feb. 28, 2021
Assets, current:
Cash and cash equivalents	$ 31,779	$ 45,120
Receivables - principally trade, less allowances of $993 and $998	429,178	382,449
Inventory	606,655	481,611
Prepaid expenses and other current assets	18,557	16,170
Income taxes receivable	3,643	6,720
Assets held for sale	1,955	39,867
Total assets, current	1,091,767	971,937
Property and equipment, net of accumulated depreciation of $151,657 and $140,379	149,738	136,535
Goodwill	739,901	739,901
Other intangible assets, net of accumulated amortization of $157,210 and $151,240	351,966	357,264
Operating lease assets	32,164	32,533
Deferred tax assets, net	28,357	21,748
Other assets	6,272	3,570
Total assets	2,400,165	2,263,488
Liabilities, current:
Accounts payable, principally trade	337,465	334,807
Accrued expenses and other current liabilities	240,636	271,179
Income taxes payable	20,091	7,022
Long-term debt, current maturities	1,884	1,884
Liabilities held for sale	159	0
Total liabilities, current	600,235	614,892
Long-term debt, excluding current maturities	470,335	341,746
Lease liabilities, non-current	36,720	38,352
Deferred tax liabilities, net	5,452	5,735
Other liabilities, non-current	19,601	23,416
Total liabilities	1,132,343	1,024,141
Commitments and contingencies
Stockholders' equity:
Cumulative preferred stock, non-voting, $1.00 par. Authorized 2,000,000 shares; none issued	0	0
Common stock, $0.10 par. Authorized 50,000,000 shares; 24,105,343 and 24,405,921 shares issued and outstanding	2,411	2,441
Additional paid in capital	291,589	283,396
Accumulated other comprehensive loss	(6,211)	(11,656)
Retained earnings	980,033	965,166
Total stockholders' equity	1,267,822	1,239,347
Total liabilities and stockholders' equity	$ 2,400,165	$ 2,263,488

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Aug. 31, 2021	Feb. 28, 2021
Statement of Financial Position [Abstract]
Allowance on receivables	$ 993	$ 998
Property and equipment, accumulated depreciation	151,657	140,379
Other intangible assets, accumulated amortization	$ 157,210	$ 151,240
Cumulative preferred stock, nonvoting, par value (in dollars per share)	$ 1	$ 1
Cumulative preferred stock, non-voting, authorized shares (in shares)	2,000,000	2,000,000
Cumulative preferred stock, non-voting, issued shares (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, authorized shares (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	24,105,343	24,405,921
Common stock, shares outstanding (in shares)	24,105,343	24,405,921

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2021	Aug. 31, 2020
Income Statement [Abstract]
Sales revenue, net	$ 475,228	$ 530,852	$ 1,016,451	$ 951,687
Cost of goods sold	264,640	300,516	585,271	542,050
Gross profit	210,588	230,336	431,180	409,637
Selling, general and administrative expense (“SG&A”)	142,928	131,027	298,679	253,016
Restructuring charges	369	34	375	367
Operating income	67,291	99,275	132,126	156,254
Non-operating income, net	31	111	133	347
Interest expense	3,307	2,796	6,302	6,642
Income before income tax	64,015	96,590	125,957	149,959
Income tax expense	12,700	9,257	17,670	2,340
Net income	$ 51,315	$ 87,333	$ 108,287	$ 147,619
Earnings per share (“EPS”):
Basic (in dollars per share)	$ 2.13	$ 3.45	$ 4.47	$ 5.84
Diluted (in dollars per share)	$ 2.11	$ 3.43	$ 4.42	$ 5.81
Weighted average shares used in computing EPS:
Basic (in shares)	24,101	25,325	24,225	25,289
Diluted (in shares)	24,347	25,458	24,492	25,428

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2021	Aug. 31, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 51,315	$ 87,333	$ 108,287	$ 147,619
Other comprehensive income (loss), net of tax:
Cash flow hedge activity - interest rate swaps	1,079	731	1,836	(1,876)
Cash flow hedge activity - foreign currency contracts	5,163	(6,134)	3,609	(5,439)
Total other comprehensive income (loss), net of tax	6,242	(5,403)	5,445	(7,315)
Comprehensive income	$ 57,557	$ 81,930	$ 113,732	$ 140,304

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Retained Earnings
Beginning balance (in shares) at Feb. 29, 2020		25,194
Beginning balance at Feb. 29, 2020	$ 1,161,723	$ 2,519	$ 268,043	$ (7,005)	$ 898,166
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	60,286				60,286
Other comprehensive income (loss), net of tax	(1,912)			(1,912)
Exercise of stock options (in shares)		8
Exercise of stock options	476	$ 1	475
Net issuance and settlement of restricted stock (in shares)		165
Issuance and settlement of restricted stock	0	$ 17	(17)
Issuance of common stock related to stock purchase plan (in shares)		15
Issuance of common stock related to stock purchase plan	1,901	$ 1	1,900
Common stock repurchased and retired (in shares)		(61)
Common stock repurchased and retired	(10,013)	$ (6)	(9,895)		(112)
Share-based compensation	9,291		9,291
Ending balance (in shares) at May. 31, 2020		25,321
Ending balance at May. 31, 2020	1,221,752	$ 2,532	269,797	(8,917)	958,340
Beginning balance (in shares) at Feb. 29, 2020		25,194
Beginning balance at Feb. 29, 2020	1,161,723	$ 2,519	268,043	(7,005)	898,166
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss), net of tax	(7,315)
Ending balance (in shares) at Aug. 31, 2020		25,328
Ending balance at Aug. 31, 2020	1,308,529	$ 2,533	274,643	(14,320)	1,045,673
Beginning balance (in shares) at May. 31, 2020		25,321
Beginning balance at May. 31, 2020	1,221,752	$ 2,532	269,797	(8,917)	958,340
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	87,333				87,333
Other comprehensive income (loss), net of tax	(5,403)			(5,403)
Exercise of stock options (in shares)		4
Exercise of stock options	371	$ 1	370
Net issuance and settlement of restricted stock (in shares)		4
Common stock repurchased and retired (in shares)		(1)
Common stock repurchased and retired	(148)		(148)
Share-based compensation	4,624		4,624
Ending balance (in shares) at Aug. 31, 2020		25,328
Ending balance at Aug. 31, 2020	1,308,529	$ 2,533	274,643	(14,320)	1,045,673
Beginning balance (in shares) at Feb. 28, 2021		24,406
Beginning balance at Feb. 28, 2021	1,239,347	$ 2,441	283,396	(11,656)	965,166
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	56,972				56,972
Other comprehensive income (loss), net of tax	(797)			(797)
Exercise of stock options (in shares)		4
Exercise of stock options	275		275
Net issuance and settlement of restricted stock (in shares)		177
Issuance and settlement of restricted stock	0	$ 18	(18)
Issuance of common stock related to stock purchase plan (in shares)		13
Issuance of common stock related to stock purchase plan	2,338	$ 1	2,337
Common stock repurchased and retired (in shares)		(502)
Common stock repurchased and retired	(110,074)	$ (50)	(16,616)		(93,408)
Share-based compensation	14,020		14,020
Ending balance (in shares) at May. 31, 2021		24,098
Ending balance at May. 31, 2021	1,202,081	$ 2,410	283,394	(12,453)	928,730
Beginning balance (in shares) at Feb. 28, 2021		24,406
Beginning balance at Feb. 28, 2021	1,239,347	$ 2,441	283,396	(11,656)	965,166
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss), net of tax	5,445
Ending balance (in shares) at Aug. 31, 2021		24,105
Ending balance at Aug. 31, 2021	1,267,822	$ 2,411	291,589	(6,211)	980,033
Beginning balance (in shares) at May. 31, 2021		24,098
Beginning balance at May. 31, 2021	1,202,081	$ 2,410	283,394	(12,453)	928,730
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	51,315				51,315
Other comprehensive income (loss), net of tax	6,242			6,242
Exercise of stock options (in shares)		6
Exercise of stock options	520	$ 1	519
Net issuance and settlement of restricted stock (in shares)		2
Issuance and settlement of restricted stock	0	$ 0	0
Common stock repurchased and retired (in shares)		(1)
Common stock repurchased and retired	(116)	$ 0	(104)		(12)
Share-based compensation	7,780		7,780
Ending balance (in shares) at Aug. 31, 2021		24,105
Ending balance at Aug. 31, 2021	$ 1,267,822	$ 2,411	$ 291,589	$ (6,211)	$ 980,033

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
Cash provided by operating activities:
Net income	$ 108,287	$ 147,619
Adjustments to reconcile net income to net cash (used) provided by operating activities:
Depreciation and amortization	17,441	18,476
Amortization of financing costs	489	522
Non-cash operating lease expense	4,434	3,151
Provision for credit losses	510	1,900
Non-cash share-based compensation	21,800	13,915
Gain on sale of North America Personal Care business	513	0
(Gain) loss on the sale or disposal of property and equipment	(1,640)	6
Deferred income taxes and tax credits	(8,207)	(535)
Changes in operating capital:
Receivables	(62,604)	(55,904)
Inventory	(124,506)	(90,094)
Prepaid expenses and other current assets	(4,982)	745
Other assets and liabilities, net	(4,545)	(5,121)
Accounts payable	6,080	127,813
Accrued expenses and other current liabilities	(26,414)	26,288
Accrued income taxes	16,032	(2,503)
Net cash (used) provided by operating activities	(58,338)	186,278
Cash provided (used) by investing activities:
Capital and intangible asset expenditures	(23,954)	(15,237)
Proceeds from sale of North America Personal Care business	44,700	0
Proceeds from the sale of property and equipment	3,208	0
Net cash provided (used) by investing activities	23,954	(15,237)
Cash provided (used) by financing activities:
Proceeds from line of credit	342,500	765,200
Repayment of line of credit	(212,500)	(799,200)
Repayment of long-term debt	(1,900)	(1,900)
Payment of financing costs	0	(3,796)
Proceeds from share issuances under share-based compensation plans	3,133	2,748
Payments for repurchases of common stock	(110,190)	(10,161)
Net cash provided (used) by financing activities	21,043	(47,109)
Net (decrease) increase in cash and cash equivalents	(13,341)	123,932
Cash and cash equivalents, beginning balance	45,120	24,467
Cash and cash equivalents, ending balance	31,779	148,399
Supplemental non-cash investing activity:
Capital Expenditures Incurred but Not yet Paid	$ 2,927	$ 0

Basis of Presentation and Relat

Basis of Presentation and Related Information	6 Months Ended
	Aug. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Related Information	Note 1 - Basis of Presentation and Related Information Corporate Overview The accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly our consolidated financial position as of August 31, 2021 and February 28, 2021, and the results of our consolidated operations for the interim periods presented. We follow the same accounting policies when preparing quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated financial statements and the notes included in our latest annual report on Form 10-K for the fiscal year ended February 28, 2021 (“Form 10-K”), and our other reports on file with the Securities and Exchange Commission (the “SEC”). When used in these notes, unless otherwise indicated or the context suggests otherwise, references to “the Company”, “our Company”, “Helen of Troy”, “we”, “us”, or “our” refer to Helen of Troy Limited and its subsidiaries, which are all wholly-owned. We refer to our common shares, par value $0.10 per share, as “common stock.” References to “the FASB” refer to the Financial Accounting Standards Board. References to “GAAP” refer to accounting principles generally accepted in the United States of America (the “U.S.”). References to “ASU” refer to the codification of GAAP in the Accounting Standards Updates issued by the FASB. References to “ASC” refer to the codification of GAAP in the Accounting Standards Codification issued by the FASB. We incorporated as Helen of Troy Corporation in Texas in 1968 and were reorganized as Helen of Troy Limited in Bermuda in 1994. We are a leading consumer products company offering creative products and solutions for our customers through a diversified portfolio of brands. As of August 31, 2021, we operated three segments: Housewares, Health & Home, and Beauty. Our Housewares segment provides a broad range of innovative consumer products for the home and on the go to help with food preparation, cooking, cleaning, organization, beverage service, and other tasks to ease everyday living for families. The Health & Home segment provides healthcare and home environment products including health care devices, water filtration systems, and small home appliances. Our Beauty segment provides mass and prestige market beauty appliance and personal care products including hair styling appliances, grooming tools, decorative haircare accessories, and liquid personal care products. Our business is seasonal due to different calendar events, holidays and seasonal weather patterns. Our fiscal reporting period ends on the last day in February. Historically, our highest sales volume and operating income occur in our third fiscal quarter ending November 30th. We purchase our products from unaffiliated manufacturers, most of which are located in China, Mexico and the U.S. During the fourth quarter of fiscal 2020, we committed to a plan to divest certain assets within our Beauty segment's mass channel personal care business, which included liquid, powder and aerosol products under brands such as Pert, Brut, Sure and Infusium (“Personal Care”). On June 7, 2021, we completed the sale of our Personal Care business, not including the Latin America and Caribbean regions, to HRB Brands LLC, for $44.7 million in cash. The net assets sold included intangible assets, inventory, certain net trade receivables, fixed assets and certain accrued sales discounts and allowances relating to our North America Personal Care business. During the second quarter of fiscal 2022, we recognized a gain on the sale totaling $0.5 million, which has been recognized in SG&A within our condensed consolidated statement of income. The transaction also includes an option that provides HRB Brands LLC the right to purchase the Latin America and Caribbean Personal Care businesses no later than the end of fiscal 2022, subject to meeting certain agreed-upon conditions. Accordingly, we have continued to classify the identified net assets of the Latin America and Caribbean Personal Care businesses as held for sale. See Note 3 for additional information. In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (“COVID-19”) to be a pandemic. The effects of the COVID-19 pandemic have had an unfavorable impact on certain parts of our business. The impact includes the effect of temporary closures of certain customer stores or limited hours of operation, and materially lower store traffic, primarily during fiscal 2021. Additionally, COVID-19 has disrupted certain parts of our supply chain. Surges in demand and shifts in shopping patterns related to COVID-19, as well as other factors, have strained the global freight network, which is resulting in higher costs, less capacity, and longer lead times. These factors may impact our ability to fulfill some orders on a timely basis. Additionally, the extent of COVID-19's impact on the demand for certain of our product lines in the future will depend on future developments, including the duration, spread and intensity of the pandemic, our continued ability to source and distribute our products, as well as any future government actions affecting consumers and the global economy generally, all of which are uncertain and difficult to predict considering the rapidly evolving landscape. Accordingly, our liquidity and financial results could be impacted in ways that we are not able to predict today. Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with GAAP and include all of our subsidiaries. Our condensed consolidated financial statements are prepared in U.S. Dollars. All intercompany balances and transactions are eliminated in consolidation. The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results may differ materially from those estimates. Reclassifications We have reclassified, combined or separately disclosed certain amounts in the prior years’ condensed consolidated financial statements and accompanying footnotes to conform with the current period’s presentation.

New Accounting Pronouncements

New Accounting Pronouncements	6 Months Ended
	Aug. 31, 2021
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	Note 2 - New Accounting Pronouncements There have been no changes in the information provided in our Form 10-K.

Assets and Liabilities Held for

Assets and Liabilities Held for Sale	6 Months Ended
	Aug. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities Held for Sale	Note 3 - Assets and Liabilities Held for Sale During the fourth quarter of fiscal 2020, we committed to a plan to divest certain assets within our Personal Care business and accordingly, we classified the identified net assets of the disposal group as held for sale. On June 7, 2021, we completed the sale of our Personal Care business, not including the Latin America and Caribbean regions, to HRB Brands LLC, for $44.7 million in cash. The net assets sold included intangible assets, inventory, certain net trade receivables, fixed assets and certain accrued sales discounts and allowances relating to our North America Personal Care business. During the second quarter of fiscal 2022, we recognized a gain on the sale totaling $0.5 million, which has been recognized in SG&A within our condensed consolidated statement of income. The transaction also includes an option that provides HRB Brands LLC the right to purchase the Latin America and Caribbean Personal Care businesses no later than the end of fiscal 2022, subject to meeting certain agreed-upon conditions. Accordingly, we have continued to classify the identified net assets of the Latin America and Caribbean Personal Care businesses as held for sale. The carrying amounts of the major classes of assets and liabilities for our Latin America and Caribbean Personal Care business that were classified as held for sale are as follows: (in thousands) August 31, 2021 February 28, 2021 Receivables, net of allowance of $34 and $30 $ 1,404 $ 7,979 Inventory 485 12,667 Property and equipment, net of accumulated depreciation of $152 and $403 66 100 Goodwill (1) — 1,397 Other intangible assets (1) — 17,724 Assets held for sale $ 1,955 $ 39,867 Accrued sales discounts and allowances $ 159 $ — Liabilities held for sale $ 159 $ —

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Aug. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 - Accrued Expenses and Other Current Liabilities A summary of accrued expenses and other current liabilities is as follows: (in thousands) August 31, 2021 February 28, 2021 Accrued compensation, benefits and payroll taxes $ 33,151 $ 66,385 Accrued sales discounts and allowances 50,686 59,426 Accrued sales returns 29,936 29,434 Accrued advertising 55,720 50,923 Other 71,143 65,011 Total accrued expenses and other current liabilities $ 240,636 $ 271,179

Share-Based Compensation Plans

Share-Based Compensation Plans	6 Months Ended
	Aug. 31, 2021
Share-based Payment Arrangement [Abstract]
Share-Based Compensation Plans	Note 5 - Share-Based Compensation Plans As part of our compensation structure, we grant share-based compensation awards to certain employees and non-employee members of our Board of Directors during the fiscal year. These awards may be subject to attainment of certain service conditions, performance conditions and/or market conditions. During the first quarter of fiscal 2022, we granted 83,227 service condition awards (“Service Condition Awards”) with a weighted average grant date fair value of $219.02. Additionally, we granted 143,340 performance-based awards during the first quarter of fiscal 2022, of which 71,670 contained performance conditions (“Performance Condition Awards”) and 71,670 contained market conditions (“Market Condition Awards”) with weighted average grant date fair values of $216.20 and $156.08, respectively. Refer to our Form 10-K for further information on the Company's share-based compensation plans. We recorded share-based compensation expense in SG&A as follows: Three Months Ended August 31, Six Months Ended August 31, (in thousands) 2021 2020 2021 2020 Stock options $ — $ 3 $ — $ 15 Directors stock compensation 163 182 323 364 Service Condition Awards 3,296 1,664 5,236 3,584 Performance Condition Awards 3,061 2,775 13,084 9,466 Market Condition Awards 1,260 — 2,389 — Employee stock purchase plan — — 768 486 Share-based compensation expense 7,780 4,624 21,800 13,915 Less income tax benefits (712) (397) (1,571) (1,003) Share-based compensation expense, net of tax $ 7,068 $ 4,227 $ 20,229 $ 12,912 Unrecognized Share-Based Compensation Expense As of August 31, 2021, our total unrecognized share-based compensation for all awards was $43.0 million, which will be recognized over a weighted average amortization period of 2.4 years. The total unrecognized share-based compensation reflects an estimate of target achievement for Performance Condition Awards granted during the first quarter of fiscal 2022 and fiscal 2021, and an estimate of 200% of target achievement for Performance Condition Awards granted in fiscal 2020.

Repurchases of Common Stock

Repurchases of Common Stock	6 Months Ended
	Aug. 31, 2021
Equity [Abstract]
Repurchase of Common Stock	Note 6 - Repurchases of Common Stock In August 2021, our Board of Directors authorized the repurchase of up to $500 million of our outstanding common stock. The authorization became effective August 25, 2021, for a period of three years, and replaced our former repurchase authorization, of which approximately $79.5 million remained. As of August 31, 2021, our entire new repurchase authorization of $500 million remained available. Our current equity-based compensation plans include provisions that allow for the “net exercise” of share-settled awards by all plan participants. In a net exercise, any required payroll taxes, federal withholding taxes and exercise price of the shares due from the equity holder can be settled by having the holder tender back to us a number of shares at fair value equal to the amounts due. Net exercises are treated as purchases and retirements of shares. The following table summarizes our share repurchase activity for the periods shown: Three Months Ended August 31, Six Months Ended August 31, (in thousands, except share and per share data) 2021 2020 2021 2020 Common stock repurchased on the open market: Number of shares — — 436,842 — Aggregate value of shares $ — $ — $ 95,484 $ — Average price per share $ — $ — $ 218.58 $ — Common stock received in connection with share-based compensation: Number of shares 503 780 66,147 61,625 Aggregate value of shares $ 116 $ 148 $ 14,706 $ 10,161 Average price per share $ 229.76 $ 189.64 $ 222.32 $ 164.88

Restructuring Plan

Restructuring Plan	6 Months Ended
	Aug. 31, 2021
Restructuring and Related Activities [Abstract]
Restructuring Plan	Note 7 - Restructuring Plan In October 2017, we announced a restructuring plan (referred to as “Project Refuel”) intended to enhance performance primarily in the Beauty and former Nutritional Supplements segments. Project Refuel includes charges for a reduction-in-force and the elimination of certain contracts. During the first quarter of fiscal 2019, we expanded Project Refuel to include the realignment and streamlining of our supply chain structure. We are targeting total annualized profit improvements of approximately $10.5 million to $12.5 million over the duration of the plan. We estimate the plan to be completed during fiscal 2022 and expect to incur total restructuring charges of approximately $10.3 million over the duration of the plan, of which $9.6 million have been incurred through the second quarter of fiscal 2022. Restructuring provisions are determined based on estimates prepared at the time the restructuring actions are approved by management and are revised periodically.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Aug. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8 - Commitments and Contingencies Legal Matters We are involved in various legal claims and proceedings in the normal course of operations. We believe the outcome of these matters will not have a material adverse effect on our consolidated financial position, results of operations or liquidity, except as described below. Regulatory Matters As a global company, we are subject to U.S. and foreign regulations, including environmental, health and safety laws, and industry-specific product certifications. Many of the products we sell are subject to product safety laws and regulations in various jurisdictions. These laws and regulations specify the maximum allowable levels of certain materials that may be contained in our products, provide statutory prohibitions against misbranded and adulterated products, establish ingredients and manufacturing procedures for certain products, specify product safety testing requirements, and set product identification, labeling and claim requirements. Additionally, some of our product lines within our Health & Home segment are subject to product identification, labeling and claim requirements, which are monitored and enforced by regulatory agencies, such as the U.S. Environmental Protection Agency (the “EPA”), U.S. Customs and Border Protection, the U.S. Food and Drug Administration, and the U.S. Consumer Product Safety Commission. In our quarterly report on Form 10-Q for our first quarter of fiscal 2022, we disclosed that we were in discussions with the EPA regarding the compliance of packaging claims on certain of our products in the air and water filtration categories and a limited subset of humidifier products within the Health & Home segment that are sold in the U.S. The EPA did not raise any product quality, safety or performance issues. As a result of these packaging compliance discussions, on May 27, 2021, we voluntarily implemented a temporary stop shipment action across this line of products in the U.S. as we worked with the EPA towards an expedient resolution. In July 2021, the EPA approved modest changes to our labeling claims on packaging of existing water filtration products, which we implemented, and subsequently began shipping in limited quantities during the second quarter of fiscal 2022. The shipping volume for these products has continued to increase and, in September 2021, we returned to a more

Long-Term Debt

Long-Term Debt	6 Months Ended
	Aug. 31, 2021
Debt Disclosure [Abstract]
Long-Term Debt	Note 9 - Long-Term Debt A summary of our long-term debt follows: (in thousands) August 31, 2021 February 28, 2021 Mississippi Business Finance Corporation Loan (the “MBFC Loan”) (1) $ 16,707 $ 18,607 Credit Agreement (2) 459,000 329,000 Subtotal 475,707 347,607 Unamortized prepaid financing fees (3,488) (3,977) Total long-term debt 472,219 343,630 Less: current maturities of long-term debt (1,884) (1,884) Long-term debt, excluding current maturities $ 470,335 $ 341,746 (1) The MBFC Loan is unsecured and bears floating interest based on either the London Interbank Offered Rate (“LIBOR”) plus a margin of up to 2.0%, or a Base Rate plus a margin of up to 1.0%, as determined by the interest rate elected and the Net Leverage Ratio defined in the loan agreement. The weighted average interest rate on borrowings outstanding was 1.1% at both August 31, 2021 and February 28, 2021. (2) The Credit Agreement (defined below) is unsecured and bears floating interest at either the Base Rate or LIBOR, plus a margin based on the Net Leverage Ratio (as defined in the Credit Agreement) of 0% to 1.0% and 1.0% to 2.0% for Base Rate and LIBOR borrowings, respectively. These floating interest rates are hedged with interest rate swaps to effectively fix interest rates on $225 million of the outstanding principal balance under the Credit Agreement (see Notes 10, 11, and 12 for additional information regarding interest rate swaps). The weighted average interest rate on borrowings outstanding was 1.1% at both August 31, 2021 and February 28, 2021. Credit Agreement We have a credit agreement (the "Credit Agreement") with Bank of America, N.A., as administrative agent, and other lenders that provides for an unsecured total revolving commitment of $1.25 billion. As of August 31, 2021, the balance of outstanding letters of credit was $34.2 million and the amount available for borrowings was $756.8 million. Covenants in the Credit Agreement limit the amount of total indebtedness we can incur. As of August 31, 2021, these covenants effectively limited our ability to incur more than $727.6 million of additional debt from all sources, including the Credit Agreement, or $756.8 million in the event a qualified acquisition is consummated. Debt Covenants As of August 31, 2021, we were in compliance with all covenants as defined under the terms of the Credit Agreement and our other debt agreements.

Fair Value

Fair Value	6 Months Ended
	Aug. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value	Note 10 - Fair Value Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques under the accounting guidance related to fair value measurements are based on observable and unobservable inputs. These inputs are classified into the following hierarchy: Level 1: Quoted prices for identical assets or liabilities in active markets; Level 2: Observable inputs other than quoted prices that are directly or indirectly observable for the asset or liability, including quoted prices for similar assets or liabilities in active markets; quoted prices for similar or identical assets or liabilities in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable; and Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. Our financial assets and liabilities are classified as Level 2 because their valuation is dependent on observable inputs and other quoted prices for similar assets or liabilities, or model-derived valuations whose significant value drivers are observable. The following tables present the carrying amount and fair value of our financial assets and liabilities measured and recorded at fair value on a recurring basis and classified as Level 2 as follows: Carrying Amount and Fair Value (in thousands) August 31, 2021 February 28, 2021 Assets: Cash equivalents (money market accounts) $ 1,098 $ 1,631 Foreign currency derivatives 535 33 Total assets $ 1,633 $ 1,664 Liabilities: Interest rate swaps $ 7,531 $ 9,941 Foreign currency derivatives 2,361 6,550 Total liabilities $ 9,892 $ 16,491 The carrying amounts of cash, accounts payable, accrued expenses and other current liabilities and income taxes payable approximate fair value because of the short maturity of these items. The carrying amounts of receivables approximate fair value due to the effect of the related allowance for credit losses. The carrying amount of our floating rate debt approximates its fair value. We use derivatives to manage our exposure to changes in foreign currency exchange rates, which can include foreign currency forward contracts, zero cost collars and cross-currency debt swaps. In addition, we use interest rate swaps to manage our exposure to changes in interest rates. All of our derivative assets and liabilities are recorded at fair value. See Notes 11 and 12 for more information on our derivatives.

Financial Instruments and Risk

Financial Instruments and Risk Management	6 Months Ended
	Aug. 31, 2021
Financial Instruments, Owned, at Fair Value [Abstract]
Financial Instruments and Risk Management	Note 11 - Financial Instruments and Risk Management Foreign Currency Risk The U.S. Dollar is the functional currency for the Company and all of its subsidiaries and is also the reporting currency for the Company. By operating internationally, we are subject to foreign currency risk from transactions denominated in currencies other than the U.S. Dollar (“foreign currencies”). Such transactions include sales, certain inventory purchases and operating expenses. As a result of such transactions, portions of our cash, trade accounts receivable and trade accounts payable are denominated in foreign currencies. Approximately 9% and 10% of our net sales revenue was denominated in foreign currencies during the three and six month periods ended August 31, 2021, respectively, compared to 10% and 13%, respectively, for the same periods last year. These sales were primarily denominated in British Pounds, Euros, Mexican Pesos and Canadian Dollars. We make most of our inventory purchases from vendors in the Asia Pacific market and primarily use the U.S. Dollar for such purchases. In our condensed consolidated statements of income, foreign currency exchange rate gains and losses resulting from the remeasurement of foreign taxes receivable, taxes payable, deferred tax assets, and deferred tax liabilities are recognized in their respective income tax lines, and all other foreign currency exchange rate gains and losses are recognized in SG&A. During the three and six month periods ended August 31, 2021, we recorded foreign currency exchange rate net losses of $0.9 million and $0.5 million, respectively, in SG&A compared to foreign currency exchange rate net gains of $1.8 million and $0.1 million, respectively, for the same periods last year. We mitigate certain foreign currency exchange rate risk by using a series of foreign currency contracts, which can include forward contracts and zero-cost collars, designated as cash flow hedges, and mark-to-market cross-currency debt swaps to protect against the foreign currency exchange rate risk inherent in our forecasted transactions denominated in foreign currencies. We do not enter into any derivatives or similar instruments for trading or other speculative purposes. Our foreign currency contracts are designated as cash flow hedges and are recorded on the balance sheet at fair value with changes in fair value recorded in Other Comprehensive Income (Loss) (“OCI”) until the hedge transaction is settled, at which point amounts are reclassified from Accumulated Other Comprehensive Income (Loss) (“AOCI”) to our condensed consolidated statements of income. Derivatives for which we have not elected hedge accounting consist of our cross-currency debt swaps, and any changes in the fair value of the derivatives are recorded in our condensed consolidated statements of income. We evaluate our derivatives designated as cash flow hedges each quarter to assess hedge effectiveness. Any ineffectiveness, which is not material for any year presented, is immediately recognized in our condensed consolidated statements of income. Interest Rate Risk Interest on our outstanding debt as of August 31, 2021 is based on floating interest rates. If short-term interest rates increase, we will incur higher interest expense on any future outstanding balances of floating rate debt. Floating interest rates are hedged with interest rate swaps to effectively fix interest rates on $225.0 million of the outstanding principal balance under the Credit Agreement, which totaled $459.0 million as of August 31, 2021. Our interest rate swaps are designated as cash flow hedges and are recorded on the balance sheet at fair value with changes in fair value recorded in OCI until the hedge transaction is settled, at which point amounts are reclassified from AOCI to our condensed consolidated statements of income. We evaluate our derivatives designated as cash flow hedges each quarter to assess hedge effectiveness. Any ineffectiveness, which is not material for any year presented, is immediately recognized in our condensed consolidated statements of income. The following tables summarize the fair values of our derivative instruments as of the end of the periods presented: (in thousands) August 31, 2021 Derivatives designated as hedging instruments Hedge Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2023 € 37,250 $ — $ 81 $ 76 $ — Forward contracts - sell Canadian Dollars Cash flow 2/2023 $ 36,500 — 136 208 — Forward contracts - sell Pounds Cash flow 2/2023 £ 32,800 — 249 844 — Forward contracts - sell Australian Dollars Cash flow 11/2021 A$ 2,000 69 — — — Interest rate swaps Cash flow 1/2024 $ 225,000 — — 3,429 4,102 Subtotal 69 466 4,557 4,102 Derivatives not designated under hedge accounting Cross-currency debt swaps - Euro (1) 4/2022 € 6,000 — — 596 — Cross-currency debt swaps - Pounds (1) 4/2022 £ 4,500 — — 637 — Subtotal — — 1,233 — Total fair value $ 69 $ 466 $ 5,790 $ 4,102 (in thousands) February 28, 2021 Derivatives designated as hedging instruments Hedge Type Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2022 € 39,000 $ — $ — $ 1,851 $ — Forward contracts - sell Canadian Dollars Cash flow 2/2023 $ 34,000 — 33 1,061 — Forward contracts - sell Pounds Cash flow 2/2023 £ 34,500 — — 2,026 21 Forward contracts - sell Australian Dollars Cash flow 11/2021 A$ 4,000 — — 18 — Interest rate swaps Cash flow 1/2024 $ 225,000 — — 4,407 5,534 Subtotal — 33 9,363 5,555 Derivatives not designated under hedge accounting Cross-currency debt swaps - Euro (1) 4/2022 € 6,000 — — — 817 Cross-currency debt swaps - Pounds (1) 4/2022 £ 4,500 — — — 756 Subtotal — — — 1,573 Total fair value $ — $ 33 $ 9,363 $ 7,128 (1) These cross-currency debt swaps, for which we have not elected hedge accounting, adjust the currency denomination of a portion of our outstanding debt to the Euro and British Pound, as applicable, for the notional amounts reported, creating an economic hedge against currency movements. The pre-tax effects of derivative instruments designated as cash flow hedges were as follows for the periods presented: Three Months Ended August 31, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2021 Location 2021 Foreign currency contracts - cash flow hedges $ 5,456 Sales revenue, net $ (861) Interest rate swaps - cash flow hedges 66 Interest expense (1,350) Total $ 5,522 $ (2,211) Three Months Ended August 31, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2020 Location 2020 Foreign currency contracts - cash flow hedges $ (7,461) SG&A $ (92) Interest rate swaps - cash flow hedges (249) Interest expense (1,207) Total $ (7,710) $ (1,299) Six Months Ended August 31, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2021 Location 2021 Foreign currency contracts - cash flow hedges $ 2,265 Sales revenue, net $ (2,087) Interest rate swaps - cash flow hedges (224) Interest expense (2,634) Total $ 2,041 $ (4,721) Six Months Ended August 31, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2020 Location 2020 Foreign currency contracts - cash flow hedges $ (5,857) SG&A $ 673 Interest rate swaps - cash flow hedges (4,382) Interest expense (1,933) Total $ (10,239) $ (1,260) The pre-tax effects of derivative instruments not designated under hedge accounting were as follows for the periods presented: Gain (Loss) Three Months Ended August 31, Six Months Ended August 31, (in thousands) Location 2021 2020 2021 2020 Cross-currency debt swaps - principal SG&A $ 469 $ (949) $ 340 $ (1,098) Cross-currency debt swaps - interest Interest expense — — (2) 74 Total $ 469 $ (949) $ 338 $ (1,024) We expect a net loss of $4.5 million associated with foreign currency contracts and interest rate swaps currently reported in AOCI to be reclassified into income over the next twelve months. The amount ultimately realized, however, will differ as exchange rates and interest rates change and the underlying contracts settle. See Notes 10 and 12 to these condensed consolidated financial statements for more information. Counterparty Credit Risk Financial instruments, including foreign currency contracts, cross-currency debt swaps and interest rate swaps, expose us to counterparty credit risk for non-performance. We manage our exposure to counterparty credit risk by only dealing with counterparties who are substantial international financial institutions with significant experience using such derivative instruments. We believe that the risk of incurring credit losses is remote.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	6 Months Ended
	Aug. 31, 2021
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Accumulated Other Comprehensive Income (Loss)	Note 12 - Accumulated Other Comprehensive Income (Loss) The changes in AOCI by component and related tax effects for the periods presented were as follows: (in thousands) Interest Foreign Total Balance at February 29, 2020 $ (8,199) $ 1,194 $ (7,005) Other comprehensive loss before reclassification (4,382) (5,857) (10,239) Amounts reclassified out of AOCI 1,933 (673) 1,260 Tax effects 573 1,091 1,664 Other comprehensive loss (1,876) (5,439) (7,315) Balance at August 31, 2020 $ (10,075) $ (4,245) $ (14,320) Balance at February 28, 2021 $ (7,576) $ (4,080) $ (11,656) Other comprehensive (loss) income before reclassification (224) 2,265 2,041 Amounts reclassified out of AOCI 2,634 2,087 4,721 Tax effects (574) (743) (1,317) Other comprehensive income 1,836 3,609 5,445 Balance at August 31, 2021 $ (5,740) $ (471) $ (6,211) See Notes 9, 10 and 11 to these condensed consolidated financial statements for additional information regarding our cash flow hedges.

Segment Information

Segment Information	6 Months Ended
	Aug. 31, 2021
Segment Reporting [Abstract]
Segment Information	Note 13 - Segment Information The following tables summarize segment information for the periods presented: Three Months Ended August 31, 2021 (in thousands) Housewares Health & Home Beauty Total Sales revenue, net $ 215,218 $ 141,479 $ 118,531 $ 475,228 Restructuring charges 369 — — 369 Operating income 41,921 4,794 20,576 67,291 Capital and intangible asset expenditures 17,050 2,232 666 19,948 Depreciation and amortization 2,815 2,624 3,289 8,728 Three Months Ended August 31, 2020 (in thousands) Housewares Health & Home Beauty Total Sales revenue, net $ 201,863 $ 211,454 $ 117,535 $ 530,852 Restructuring charges 25 — 9 34 Operating income 45,403 33,771 20,101 99,275 Capital and intangible asset expenditures 2,820 4,497 1,469 8,786 Depreciation and amortization 2,250 4,173 2,913 9,336 Six Months Ended August 31, 2021 (in thousands) Housewares Health & Home Beauty Total Sales revenue, net $ 408,862 $ 345,575 $ 262,014 $ 1,016,451 Restructuring charges 369 — 6 375 Operating income 69,064 16,043 47,019 132,126 Capital and intangible asset expenditures 20,037 2,980 937 23,954 Depreciation and amortization 5,363 5,350 6,728 17,441 Six Months Ended August 31, 2020 (in thousands) Housewares Health & Home Beauty Total Sales revenue, net $ 342,491 $ 411,410 $ 197,786 $ 951,687 Restructuring charges 263 — 104 367 Operating income 68,636 65,304 22,314 156,254 Capital and intangible asset expenditures 5,537 7,905 1,795 15,237 Depreciation and amortization 4,372 8,225 5,879 18,476

Income Taxes

Income Taxes	6 Months Ended
	Aug. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 14 - Income Taxes We reorganized the Company in Bermuda in 1994 and many of our foreign subsidiaries are not directly or indirectly owned by a U.S. parent. As such, a large portion of our foreign income is not subject to U.S. taxation on a permanent basis under current law. Additionally, our intellectual property is largely owned by foreign subsidiaries, resulting in proportionally higher earnings in jurisdictions with lower statutory tax rates, which decreases our overall effective tax rate. The taxable income earned in each jurisdiction, whether U.S. or foreign, is determined by the subsidiary's operating results and transfer pricing and tax regulations in the related jurisdictions. For interim periods, our income tax expense and resulting effective tax rate are based upon an estimated annual effective tax rate adjusted for the effects of items required to be treated as discrete to the period, including changes in tax laws, changes in estimated exposures for uncertain tax positions and other items. On March 11, 2021, the American Rescue Plan Act (the “ARP”) was enacted and signed into law. The ARP is an economic stimulus package in response to the COVID-19 outbreak which contains tax provisions that did not have a material impact to our condensed consolidated financial statements. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) was enacted and signed into law. The CARES Act is an emergency economic stimulus package in response to the COVID-19 outbreak that contains numerous tax provisions. Among other things, the CARES Act included technical corrections to the effective date language in the Tax Cuts and Jobs Act, enacted into law on December 22, 2017 (the “Tax Act”), related to net operating loss carrybacks. Upon the enactment of the Tax Act in fiscal 2018, there was a net operating loss on our balance sheet, which was measured using the U.S. statutory tax rate in effect prior to enactment. As a result of the Tax Act, we were required to record a one-time charge of $17.9 million in fiscal 2018, which included a charge of $9.4 million to remeasure the net operating loss at the reduced rate at which it was expected to reverse in the future. The CARES Act effectively reversed the impact of the Tax Act on our net operating loss, resulting in a corresponding tax benefit of $9.4 million recorded in the first quarter of fiscal 2021. For the three months ended August 31, 2021, income tax expense as a percentage of income before income tax was 19.8% compared to 9.6% for the same period last year. The year-over-year increase in the effective tax rate is primarily due to shifts in the mix of taxable income in our various tax jurisdictions. For the six months ended August 31, 2021, income tax expense as a percentage of income before income tax was 14.0% compared to 1.6% for the same period last year, primarily due to the mix of taxable income in our various tax jurisdictions, the benefit of the CARES Act in fiscal 2021 and excess tax benefits associated with share-based compensation recognized in the period in which it is settled. Our Macau subsidiary generates income from the sale of the goods that it has sourced and procured. This subsidiary is responsible for the sourcing and procurement of a large portion of the products that we sell. We previously had an indefinite tax holiday in Macau conditioned on the subsidiary meeting certain employment and investment thresholds. The Macau Offshore Law and its supplementary regulations that grant tax incentives to approved offshore institutions was abolished on January 1, 2021. Existing approved offshore institutions such as ours continued to operate under the offshore regime until the end of the calendar year 2020. Beginning in calendar year 2021, our Macau subsidiary transitioned to onshore status and is now subject to a statutory corporate income tax of 12%. Because our Macau subsidiary is not directly or indirectly owned by a U.S. parent, there is no U.S. tax liability associated with the income generated in Macau.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Aug. 31, 2021
Earnings Per Share [Abstract]
Earnings Per Share	Note 15 - Earnings Per Share We compute basic earnings per share using the weighted average number of shares of common stock outstanding during the period. We compute diluted earnings per share using the weighted average number of shares of common stock outstanding plus the effect of dilutive securities. Dilutive securities at any given point in time may consist of outstanding options to purchase common stock and issued and contingently issuable unvested restricted stock units, performance stock units, restricted stock awards and performance restricted stock awards and other stock based awards. Anti-dilutive securities are not included in the computation of diluted earnings per share under the treasury stock method. See Note 5 to these condensed consolidated financial statements for more information regarding stock-based awards. The following table presents our weighted average basic and diluted shares outstanding for the periods shown: Three Months Ended August 31, Six Months Ended August 31, (in thousands) 2021 2020 2021 2020 Weighted average shares outstanding, basic 24,101 25,325 24,225 25,289 Incremental shares from share-based compensation arrangements 246 133 267 139 Weighted average shares outstanding, diluted 24,347 25,458 24,492 25,428 Anti-dilutive securities 29 180 15 221

Basis of Presentation and Rel_2

Basis of Presentation and Related Information (Policies)	6 Months Ended
	Aug. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with GAAP and include all of our subsidiaries. Our condensed consolidated financial statements are prepared in U.S. Dollars. All intercompany balances and transactions are eliminated in consolidation. The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results may differ materially from those estimates.
Reclassification	Reclassifications We have reclassified, combined or separately disclosed certain amounts in the prior years’ condensed consolidated financial statements and accompanying footnotes to conform with the current period’s presentation.

Assets and Liabilities Held f_2

Assets and Liabilities Held for Sale (Tables)	6 Months Ended
	Aug. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Carrying amounts of major asset classes for Personal Care classified as held-for-sale	The carrying amounts of the major classes of assets and liabilities for our Latin America and Caribbean Personal Care business that were classified as held for sale are as follows: (in thousands) August 31, 2021 February 28, 2021 Receivables, net of allowance of $34 and $30 $ 1,404 $ 7,979 Inventory 485 12,667 Property and equipment, net of accumulated depreciation of $152 and $403 66 100 Goodwill (1) — 1,397 Other intangible assets (1) — 17,724 Assets held for sale $ 1,955 $ 39,867 Accrued sales discounts and allowances $ 159 $ — Liabilities held for sale $ 159 $ —

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Aug. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Schedule of accrued expenses and other current liabilities	A summary of accrued expenses and other current liabilities is as follows: (in thousands) August 31, 2021 February 28, 2021 Accrued compensation, benefits and payroll taxes $ 33,151 $ 66,385 Accrued sales discounts and allowances 50,686 59,426 Accrued sales returns 29,936 29,434 Accrued advertising 55,720 50,923 Other 71,143 65,011 Total accrued expenses and other current liabilities $ 240,636 $ 271,179

Share-Based Compensation Plans

Share-Based Compensation Plans (Tables)	6 Months Ended
	Aug. 31, 2021
Share-based Payment Arrangement [Abstract]
Share-based compensation expense in SG&A	We recorded share-based compensation expense in SG&A as follows: Three Months Ended August 31, Six Months Ended August 31, (in thousands) 2021 2020 2021 2020 Stock options $ — $ 3 $ — $ 15 Directors stock compensation 163 182 323 364 Service Condition Awards 3,296 1,664 5,236 3,584 Performance Condition Awards 3,061 2,775 13,084 9,466 Market Condition Awards 1,260 — 2,389 — Employee stock purchase plan — — 768 486 Share-based compensation expense 7,780 4,624 21,800 13,915 Less income tax benefits (712) (397) (1,571) (1,003) Share-based compensation expense, net of tax $ 7,068 $ 4,227 $ 20,229 $ 12,912

Repurchase of Helen of Troy Com

Repurchase of Helen of Troy Common Stock (Tables)	6 Months Ended
	Aug. 31, 2021
Equity [Abstract]
Summary of share repurchase activity	The following table summarizes our share repurchase activity for the periods shown: Three Months Ended August 31, Six Months Ended August 31, (in thousands, except share and per share data) 2021 2020 2021 2020 Common stock repurchased on the open market: Number of shares — — 436,842 — Aggregate value of shares $ — $ — $ 95,484 $ — Average price per share $ — $ — $ 218.58 $ — Common stock received in connection with share-based compensation: Number of shares 503 780 66,147 61,625 Aggregate value of shares $ 116 $ 148 $ 14,706 $ 10,161 Average price per share $ 229.76 $ 189.64 $ 222.32 $ 164.88

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Aug. 31, 2021
Debt Disclosure [Abstract]
Summary of long-term debt	A summary of our long-term debt follows: (in thousands) August 31, 2021 February 28, 2021 Mississippi Business Finance Corporation Loan (the “MBFC Loan”) (1) $ 16,707 $ 18,607 Credit Agreement (2) 459,000 329,000 Subtotal 475,707 347,607 Unamortized prepaid financing fees (3,488) (3,977) Total long-term debt 472,219 343,630 Less: current maturities of long-term debt (1,884) (1,884) Long-term debt, excluding current maturities $ 470,335 $ 341,746 (1) The MBFC Loan is unsecured and bears floating interest based on either the London Interbank Offered Rate (“LIBOR”) plus a margin of up to 2.0%, or a Base Rate plus a margin of up to 1.0%, as determined by the interest rate elected and the Net Leverage Ratio defined in the loan agreement. The weighted average interest rate on borrowings outstanding was 1.1% at both August 31, 2021 and February 28, 2021. (2) The Credit Agreement (defined below) is unsecured and bears floating interest at either the Base Rate or LIBOR, plus a margin based on the Net Leverage Ratio (as defined in the Credit Agreement) of 0% to 1.0% and 1.0% to 2.0% for Base Rate and LIBOR borrowings, respectively. These floating interest rates are hedged with interest rate swaps to effectively fix interest rates on $225 million of the outstanding principal balance under the Credit Agreement (see Notes 10, 11, and 12 for additional information regarding interest rate swaps). The weighted average interest rate on borrowings outstanding was 1.1% at both August 31, 2021 and February 28, 2021.

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Aug. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of fair value hierarchy of financial assets and liabilities presented at fair value and measured on a recurring basis	The following tables present the carrying amount and fair value of our financial assets and liabilities measured and recorded at fair value on a recurring basis and classified as Level 2 as follows: Carrying Amount and Fair Value (in thousands) August 31, 2021 February 28, 2021 Assets: Cash equivalents (money market accounts) $ 1,098 $ 1,631 Foreign currency derivatives 535 33 Total assets $ 1,633 $ 1,664 Liabilities: Interest rate swaps $ 7,531 $ 9,941 Foreign currency derivatives 2,361 6,550 Total liabilities $ 9,892 $ 16,491

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	6 Months Ended
	Aug. 31, 2021
Financial Instruments, Owned, at Fair Value [Abstract]
Schedule of fair values of derivative instruments	The following tables summarize the fair values of our derivative instruments as of the end of the periods presented: (in thousands) August 31, 2021 Derivatives designated as hedging instruments Hedge Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2023 € 37,250 $ — $ 81 $ 76 $ — Forward contracts - sell Canadian Dollars Cash flow 2/2023 $ 36,500 — 136 208 — Forward contracts - sell Pounds Cash flow 2/2023 £ 32,800 — 249 844 — Forward contracts - sell Australian Dollars Cash flow 11/2021 A$ 2,000 69 — — — Interest rate swaps Cash flow 1/2024 $ 225,000 — — 3,429 4,102 Subtotal 69 466 4,557 4,102 Derivatives not designated under hedge accounting Cross-currency debt swaps - Euro (1) 4/2022 € 6,000 — — 596 — Cross-currency debt swaps - Pounds (1) 4/2022 £ 4,500 — — 637 — Subtotal — — 1,233 — Total fair value $ 69 $ 466 $ 5,790 $ 4,102 (in thousands) February 28, 2021 Derivatives designated as hedging instruments Hedge Type Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2022 € 39,000 $ — $ — $ 1,851 $ — Forward contracts - sell Canadian Dollars Cash flow 2/2023 $ 34,000 — 33 1,061 — Forward contracts - sell Pounds Cash flow 2/2023 £ 34,500 — — 2,026 21 Forward contracts - sell Australian Dollars Cash flow 11/2021 A$ 4,000 — — 18 — Interest rate swaps Cash flow 1/2024 $ 225,000 — — 4,407 5,534 Subtotal — 33 9,363 5,555 Derivatives not designated under hedge accounting Cross-currency debt swaps - Euro (1) 4/2022 € 6,000 — — — 817 Cross-currency debt swaps - Pounds (1) 4/2022 £ 4,500 — — — 756 Subtotal — — — 1,573 Total fair value $ — $ 33 $ 9,363 $ 7,128 (1) These cross-currency debt swaps, for which we have not elected hedge accounting, adjust the currency denomination of a portion of our outstanding debt to the Euro and British Pound, as applicable, for the notional amounts reported, creating an economic hedge against currency movements.
Schedule of pre-tax effect of derivative instruments designated as hedges	The pre-tax effects of derivative instruments designated as cash flow hedges were as follows for the periods presented: Three Months Ended August 31, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2021 Location 2021 Foreign currency contracts - cash flow hedges $ 5,456 Sales revenue, net $ (861) Interest rate swaps - cash flow hedges 66 Interest expense (1,350) Total $ 5,522 $ (2,211) Three Months Ended August 31, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2020 Location 2020 Foreign currency contracts - cash flow hedges $ (7,461) SG&A $ (92) Interest rate swaps - cash flow hedges (249) Interest expense (1,207) Total $ (7,710) $ (1,299) Six Months Ended August 31, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2021 Location 2021 Foreign currency contracts - cash flow hedges $ 2,265 Sales revenue, net $ (2,087) Interest rate swaps - cash flow hedges (224) Interest expense (2,634) Total $ 2,041 $ (4,721) Six Months Ended August 31, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2020 Location 2020 Foreign currency contracts - cash flow hedges $ (5,857) SG&A $ 673 Interest rate swaps - cash flow hedges (4,382) Interest expense (1,933) Total $ (10,239) $ (1,260)
Schedule of pre-tax effect of derivative instruments not designated as hedges	The pre-tax effects of derivative instruments not designated under hedge accounting were as follows for the periods presented: Gain (Loss) Three Months Ended August 31, Six Months Ended August 31, (in thousands) Location 2021 2020 2021 2020 Cross-currency debt swaps - principal SG&A $ 469 $ (949) $ 340 $ (1,098) Cross-currency debt swaps - interest Interest expense — — (2) 74 Total $ 469 $ (949) $ 338 $ (1,024)

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Aug. 31, 2021
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Summary of changes in accumulated other comprehensive income (loss)	The changes in AOCI by component and related tax effects for the periods presented were as follows: (in thousands) Interest Foreign Total Balance at February 29, 2020 $ (8,199) $ 1,194 $ (7,005) Other comprehensive loss before reclassification (4,382) (5,857) (10,239) Amounts reclassified out of AOCI 1,933 (673) 1,260 Tax effects 573 1,091 1,664 Other comprehensive loss (1,876) (5,439) (7,315) Balance at August 31, 2020 $ (10,075) $ (4,245) $ (14,320) Balance at February 28, 2021 $ (7,576) $ (4,080) $ (11,656) Other comprehensive (loss) income before reclassification (224) 2,265 2,041 Amounts reclassified out of AOCI 2,634 2,087 4,721 Tax effects (574) (743) (1,317) Other comprehensive income 1,836 3,609 5,445 Balance at August 31, 2021 $ (5,740) $ (471) $ (6,211)

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Aug. 31, 2021
Segment Reporting [Abstract]
Schedule of segment information	The following tables summarize segment information for the periods presented: Three Months Ended August 31, 2021 (in thousands) Housewares Health & Home Beauty Total Sales revenue, net $ 215,218 $ 141,479 $ 118,531 $ 475,228 Restructuring charges 369 — — 369 Operating income 41,921 4,794 20,576 67,291 Capital and intangible asset expenditures 17,050 2,232 666 19,948 Depreciation and amortization 2,815 2,624 3,289 8,728 Three Months Ended August 31, 2020 (in thousands) Housewares Health & Home Beauty Total Sales revenue, net $ 201,863 $ 211,454 $ 117,535 $ 530,852 Restructuring charges 25 — 9 34 Operating income 45,403 33,771 20,101 99,275 Capital and intangible asset expenditures 2,820 4,497 1,469 8,786 Depreciation and amortization 2,250 4,173 2,913 9,336 Six Months Ended August 31, 2021 (in thousands) Housewares Health & Home Beauty Total Sales revenue, net $ 408,862 $ 345,575 $ 262,014 $ 1,016,451 Restructuring charges 369 — 6 375 Operating income 69,064 16,043 47,019 132,126 Capital and intangible asset expenditures 20,037 2,980 937 23,954 Depreciation and amortization 5,363 5,350 6,728 17,441 Six Months Ended August 31, 2020 (in thousands) Housewares Health & Home Beauty Total Sales revenue, net $ 342,491 $ 411,410 $ 197,786 $ 951,687 Restructuring charges 263 — 104 367 Operating income 68,636 65,304 22,314 156,254 Capital and intangible asset expenditures 5,537 7,905 1,795 15,237 Depreciation and amortization 4,372 8,225 5,879 18,476

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Aug. 31, 2021
Earnings Per Share [Abstract]
Schedule of components of basic and diluted shares	The following table presents our weighted average basic and diluted shares outstanding for the periods shown: Three Months Ended August 31, Six Months Ended August 31, (in thousands) 2021 2020 2021 2020 Weighted average shares outstanding, basic 24,101 25,325 24,225 25,289 Incremental shares from share-based compensation arrangements 246 133 267 139 Weighted average shares outstanding, diluted 24,347 25,458 24,492 25,428 Anti-dilutive securities 29 180 15 221

Basis of Presentation and Rel_3

Basis of Presentation and Related Information (Details) $ / shares in Units, $ in Thousands	Jun. 07, 2021USD ($)	Aug. 31, 2021USD ($)Segment$ / shares	Aug. 31, 2020USD ($)	Feb. 28, 2021$ / shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Common shares, par value (in dollars per share) | $ / shares		$ 0.10		$ 0.10
Number of segments | Segment		3
Proceeds from sale of North America Personal Care business	$ 44,700	$ 44,700	$ 0
Gain on sale of North America Personal Care business	$ (500)	$ (513)	$ 0

Assets and Liabilities Held f_3

Assets and Liabilities Held for Sale- Narrative (Details) - USD ($) $ in Thousands	Jun. 07, 2021	Aug. 31, 2021	Aug. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Proceeds from sale of North America Personal Care business	$ 44,700	$ 44,700	$ 0
Gain on sale of North America Personal Care business	$ (500)	$ (513)	$ 0

Assets and Liabilities Held f_4

Assets and Liabilities Held for Sale (Details) - USD ($) $ in Thousands	Aug. 31, 2021	Feb. 28, 2021
Long Lived Assets Held-for-sale [Line Items]
Assets held for sale	$ 1,955	$ 39,867
Liabilities held for sale	159	0
Allowance on receivables	993	998
Property and equipment, accumulated depreciation	151,657	140,379
Other intangible assets, accumulated amortization	157,210	151,240
Personal Care
Long Lived Assets Held-for-sale [Line Items]
Assets held for sale	1,955	39,867
Liabilities held for sale	159	0
Allowance on receivables	34	30
Goodwill accumulated impairment	80,445	80,445
Personal Care | Accrued sales discounts and allowances
Long Lived Assets Held-for-sale [Line Items]
Liabilities held for sale	159	0
Other Intangible Assets, Held-For-Sale | Personal Care
Long Lived Assets Held-for-sale [Line Items]
Other intangible assets, accumulated amortization	4,474	4,474
Property, Plant and Equipment, Held-for-Sale | Personal Care
Long Lived Assets Held-for-sale [Line Items]
Property and equipment, accumulated depreciation	152	403
Receivables, net of allowance of $34 and $30 | Personal Care
Long Lived Assets Held-for-sale [Line Items]
Assets held for sale	1,404	7,979
Inventory | Personal Care
Long Lived Assets Held-for-sale [Line Items]
Assets held for sale	485	12,667
Property and equipment, net of accumulated depreciation of $152 and $403 | Personal Care
Long Lived Assets Held-for-sale [Line Items]
Assets held for sale	66	100
Goodwill | Personal Care
Long Lived Assets Held-for-sale [Line Items]
Assets held for sale	0	1,397
Other intangible assets | Personal Care
Long Lived Assets Held-for-sale [Line Items]
Assets held for sale	$ 0	$ 17,724

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Aug. 31, 2021	Feb. 28, 2021
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued compensation, benefits and payroll taxes	$ 33,151	$ 66,385
Accrued sales discounts and allowances	50,686	59,426
Accrued sales returns	29,936	29,434
Accrued advertising	55,720	50,923
Other	71,143	65,011
Total accrued expenses and other current liabilities	$ 240,636	$ 271,179

Share-Based Compensation Plan_2

Share-Based Compensation Plans (Details) $ / shares in Units, $ in Millions	3 Months Ended	6 Months Ended
	Aug. 31, 2021USD ($)$ / sharesshares	Aug. 31, 2021USD ($)
Share-based compensation plans
Expected recognition period for unrecognized share-based compensation		2 years 4 months 24 days
Target achievement for Performance Condition Awards, as a percentage	200.00%	200.00%
Restricted Stock
Share-based compensation plans
Number of awards granted (in shares)	143,340
Unrecognized share-based compensation | $	$ 43	$ 43
Service Condition Awards
Share-based compensation plans
Number of awards granted (in shares)	83,227
Grant date fair value of shares granted in period (in dollars per share) | $ / shares	$ 219.02
Market Condition Awards
Share-based compensation plans
Number of awards granted (in shares)	71,670
Grant date fair value of shares granted in period (in dollars per share) | $ / shares	$ 156.08
Performance Condition Awards
Share-based compensation plans
Number of awards granted (in shares)	71,670
Grant date fair value of shares granted in period (in dollars per share) | $ / shares	$ 216.20

Share-Based Compensation Plan_3

Share-Based Compensation Plans Share Based Compensation Expense in SG&A (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2021	Aug. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense, net of tax	$ 7,068	$ 4,227	$ 20,229	$ 12,912
SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	7,780	4,624	21,800	13,915
Less income tax benefits	(712)	(397)	(1,571)	(1,003)
Stock options | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	0	3	0	15
Service Condition Awards | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	3,296	1,664	5,236	3,584
Performance Condition Awards | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	3,061	2,775	13,084	9,466
Market Condition Awards | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	1,260	0	2,389	0
Employee stock purchase plan | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	0	0	768	486
Directors stock compensation | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 163	$ 182	$ 323	$ 364

Repurchase of Common Stock (Det

Repurchase of Common Stock (Details) - USD ($)	1 Months Ended
	Aug. 31, 2021	Aug. 24, 2021
Equity [Abstract]
Amount of shares authorized for purchase	$ 500,000,000
Period for stock repurchase	3 years
Remaining share repurchase amount	$ 500,000,000	$ 79,500,000

Repurchase of Common Stock - Su

Repurchase of Common Stock - Summary of share repurpose activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Aug. 31, 2021	May 31, 2021	Aug. 31, 2020	May 31, 2020	Aug. 31, 2021	Aug. 31, 2020
Repurchase of common stock
Aggregate value of shares	$ 116	$ 110,074	$ 148	$ 10,013
Stock Compensation Plan
Repurchase of common stock
Number of shares (in shares)	503		780,000		66,147	61,625,000
Aggregate value of shares	$ 116		$ 148		$ 14,706	$ 10,161
Average price per share (in dollars per share)	$ 229.76		$ 189.64		$ 222.32	$ 164.88
Open Market
Repurchase of common stock
Number of shares (in shares)	0		0		436,842	0
Aggregate value of shares	$ 0		$ 0		$ 95,484	$ 0
Average price per share (in dollars per share)	$ 0		$ 0		$ 218.58	$ 0

Restructuring Plan (Details)

Restructuring Plan (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		47 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2021	Feb. 28, 2022
Restructuring Plan
Restructuring charges	$ 369	$ 34	$ 375	$ 367
Project Refuel
Restructuring Plan
Incurred pre-tax restructuring costs	9,600		9,600		$ 9,600
Restructuring charges	400		400
Cash restructuring payments for the reporting period	300		400
Cash restructuring payments to date					9,500
Restructuring liability	$ 100		$ 100		100
Minimum | Project Refuel
Restructuring Plan
Targeted annualized profit improvement					10,500
Maximum | Project Refuel
Restructuring Plan
Targeted annualized profit improvement					$ 12,500
Scenario, Forecast | Project Refuel
Restructuring Plan
Expected restructuring costs						$ 10,300

Commitments and Contingencies (

Commitments and Contingencies (Details) - Health & Home - USD ($) $ in Millions	3 Months Ended
	Aug. 31, 2021	May 31, 2021
EPA Remediation Costs
Commitments and contingencies
Charge to write off obsolete packaging	$ 3	$ 13.1
Legal Fees | SG&A
Commitments and contingencies
Charge to write off obsolete packaging	2.6
Storage And Obsolete Packaging
Commitments and contingencies
Charge to write off obsolete packaging	$ 0.4

Long-Term Debt - Schedule (Deta

Long-Term Debt - Schedule (Details) - USD ($) $ in Thousands	6 Months Ended
	Aug. 31, 2021	Feb. 28, 2021
Long-term debt
Aggregate principal balance	$ 475,707	$ 347,607
Unamortized prepaid financing fees	(3,488)	(3,977)
Total long-term debt	472,219	343,630
Less: current maturities of long-term debt	(1,884)	(1,884)
Long-term debt, excluding current maturities	470,335	341,746
MBFC loan
Long-term debt
Aggregate principal balance	$ 16,707	$ 18,607
Weighted average effective interest rate	1.10%	1.10%
MBFC loan | Base rate
Long-term debt
Interest rate	1.00%
MBFC loan | LIBOR
Long-term debt
Interest rate	2.00%
Credit agreement
Long-term debt
Aggregate principal balance	$ 459,000	$ 329,000
Weighted average effective interest rate	1.10%	1.10%
Fixed rate debt	$ 225,000
Credit agreement | Minimum | Base rate
Long-term debt
Interest rate	0.00%
Credit agreement | Minimum | LIBOR
Long-term debt
Interest rate	1.00%
Credit agreement | Maximum | Base rate
Long-term debt
Interest rate	1.00%
Credit agreement | Maximum | LIBOR
Long-term debt
Interest rate	2.00%

Long-Term Debt (Details)

Long-Term Debt (Details) $ in Millions	Aug. 31, 2021USD ($)
Debt Instrument [Line Items]
Maximum additional debt allowed under debt covenants	$ 727.6
Maximum additional debt allowed in the event a qualified acquisition is consummated	756.8
Revolving loan
Debt Instrument [Line Items]
Maximum revolving commitment	1,250
Credit agreement | Letter of credit
Debt Instrument [Line Items]
Amount outstanding, letters of credit	34.2
MBFC loan
Debt Instrument [Line Items]
Amount available for borrowings	$ 756.8

Fair Value (Details)

Fair Value (Details) - Recurring - Fair Values - Fair Value, Inputs, Level 2 - USD ($) $ in Thousands	Aug. 31, 2021	Feb. 28, 2021
Assets:
Total assets	$ 1,633	$ 1,664
Liabilities:
Total liabilities	9,892	16,491
Interest rate swap
Liabilities:
Derivative liabilities	7,531	9,941
Foreign currency contracts
Assets:
Foreign currency derivatives	535	33
Liabilities:
Derivative liabilities	2,361	6,550
Money market accounts
Assets:
Cash equivalents (money market accounts)	$ 1,098	$ 1,631

Financial Instruments and Ris_3

Financial Instruments and Risk Management (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2021	Aug. 31, 2020	Feb. 28, 2021
Foreign Currency Risk and Currency Exchange Uncertainties
Aggregate principal balance	$ 475,707		$ 475,707		$ 347,607
Credit agreement
Foreign Currency Risk and Currency Exchange Uncertainties
Fixed rate debt	225,000		225,000
Aggregate principal balance	459,000		459,000		$ 329,000
SG&A
Foreign Currency Risk and Currency Exchange Uncertainties
Net foreign exchange gains (losses), including the impact of currency hedges and currency swaps	$ (900)	$ 1,800	$ (500)	$ 100
Net sales revenue | Geographic concentration | International operations - transactions denominated in foreign currencies
Foreign Currency Risk and Currency Exchange Uncertainties
Concentration risk percentage	9.00%	10.00%	10.00%	13.00%

Financial Instruments and Ris_4

Financial Instruments and Risk Management - Derivative FV (Details) € in Thousands, £ in Thousands, $ in Thousands, $ in Thousands, $ in Thousands	Aug. 31, 2021EUR (€)	Aug. 31, 2021USD ($)	Aug. 31, 2021CAD ($)	Aug. 31, 2021GBP (£)	Aug. 31, 2021AUD ($)	Feb. 28, 2021EUR (€)	Feb. 28, 2021USD ($)	Feb. 28, 2021CAD ($)	Feb. 28, 2021GBP (£)	Feb. 28, 2021AUD ($)
Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		$ 69					$ 0
Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		466					33
Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		5,790					9,363
Other Liabilities, Non- current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		4,102					7,128
Derivatives designated as hedging instruments | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		69					0
Derivatives designated as hedging instruments | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		466					33
Derivatives designated as hedging instruments | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		4,557					9,363
Derivatives designated as hedging instruments | Other Liabilities, Non- current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		4,102					5,555
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Euros
Fair values of derivative instruments in the consolidated balance sheet
Notional amount | €	€ 37,250					€ 39,000
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Euros | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Euros | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		81					0
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Euros | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		76					1,851
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Euros | Other Liabilities, Non- current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Canadian Dollars
Fair values of derivative instruments in the consolidated balance sheet
Notional amount			$ 36,500					$ 34,000
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Canadian Dollars | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Canadian Dollars | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		136					33
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Canadian Dollars | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		208					1,061
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Canadian Dollars | Other Liabilities, Non- current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Pounds
Fair values of derivative instruments in the consolidated balance sheet
Notional amount | £									£ 34,500
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Pounds | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets							0
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Pounds | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets							0
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Pounds | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities							2,026
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Pounds | Other Liabilities, Non- current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities							21
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Australian Dollars
Fair values of derivative instruments in the consolidated balance sheet
Notional amount					$ 2,000					$ 4,000
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Australian Dollars | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		69					0
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Australian Dollars | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Australian Dollars | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					18
Derivatives designated as hedging instruments | Foreign currency contracts | Sell | Australian Dollars | Other Liabilities, Non- current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Zero-cost collar contract | Sell | Pounds
Fair values of derivative instruments in the consolidated balance sheet
Notional amount | £				£ 32,800
Derivatives designated as hedging instruments | Zero-cost collar contract | Sell | Pounds | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0
Derivatives designated as hedging instruments | Zero-cost collar contract | Sell | Pounds | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		249
Derivatives designated as hedging instruments | Zero-cost collar contract | Sell | Pounds | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		844
Derivatives designated as hedging instruments | Zero-cost collar contract | Sell | Pounds | Other Liabilities, Non- current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0
Derivatives designated as hedging instruments | Interest rate swaps
Fair values of derivative instruments in the consolidated balance sheet
Notional amount		225,000					225,000
Derivatives designated as hedging instruments | Interest rate swaps | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives designated as hedging instruments | Interest rate swaps | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives designated as hedging instruments | Interest rate swaps | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		3,429					4,407
Derivatives designated as hedging instruments | Interest rate swaps | Other Liabilities, Non- current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		4,102					5,534
Derivatives not designated under hedge accounting | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives not designated under hedge accounting | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives not designated under hedge accounting | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		1,233					0
Derivatives not designated under hedge accounting | Other Liabilities, Non- current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					1,573
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros
Fair values of derivative instruments in the consolidated balance sheet
Notional amount | €	€ 6,000					€ 6,000
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		596					0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Other Liabilities, Non- current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					817
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds
Fair values of derivative instruments in the consolidated balance sheet
Notional amount | £				£ 4,500					£ 4,500
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		637					0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Other Liabilities, Non- current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		$ 0					$ 756

Financial Instruments and Ris_5

Financial Instruments and Risk Management - Derivative tax effect (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2021	Aug. 31, 2020
Pre-tax effect of derivative instruments
Gain (Loss) Recognized in AOCI	$ 5,522	$ (7,710)	$ 2,041	$ (10,239)
Gain (Loss) Reclassified from AOCI into Income	(2,211)	(1,299)	(4,721)	(1,260)
Gain (Loss)  Recognized in Income	469	(949)	338	(1,024)
Foreign currency contracts | Cash flow hedges
Pre-tax effect of derivative instruments
Gain (Loss) Recognized in AOCI	5,456	(7,461)	2,265	(5,857)
Net loss currently reported in accumulated other comprehensive income, to be reclassified into income			$ 4,500
Net loss currently reported in accumulated other comprehensive income, to be reclassified into income, period of time to transfer			12 months
Foreign currency contracts | Cash flow hedges | SG&A
Pre-tax effect of derivative instruments
Gain (Loss) Reclassified from AOCI into Income	(861)	(92)	$ (2,087)	673
Interest rate swaps | Cash flow hedges
Pre-tax effect of derivative instruments
Gain (Loss) Recognized in AOCI	66	(249)	(224)	(4,382)
Interest rate swaps | Cash flow hedges | Interest expense
Pre-tax effect of derivative instruments
Gain (Loss) Reclassified from AOCI into Income	(1,350)	(1,207)	(2,634)	(1,933)
Cross currency debt swaps | SG&A
Pre-tax effect of derivative instruments
Gain (Loss)  Recognized in Income	469	(949)	340	(1,098)
Cross currency debt swaps | Interest expense
Pre-tax effect of derivative instruments
Gain (Loss)  Recognized in Income	$ 0	$ 0	$ (2)	$ 74

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Aug. 31, 2021	May 31, 2021	Aug. 31, 2020	May 31, 2020	Aug. 31, 2021	Aug. 31, 2020
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 1,202,081	$ 1,239,347	$ 1,221,752	$ 1,161,723	$ 1,239,347	$ 1,161,723
Other comprehensive (loss) income before reclassification					2,041	(10,239)
Amounts reclassified out of AOCI					4,721	1,260
Tax effects					(1,317)	1,664
Total other comprehensive income (loss), net of tax	6,242	(797)	(5,403)	(1,912)	5,445	(7,315)
Ending balance	1,267,822	1,202,081	1,308,529	1,221,752	1,267,822	1,308,529
Interest Rate Swaps
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(7,576)		(8,199)	(7,576)	(8,199)
Other comprehensive (loss) income before reclassification					(224)	(4,382)
Amounts reclassified out of AOCI					2,634	1,933
Tax effects					(574)	573
Total other comprehensive income (loss), net of tax					1,836	(1,876)
Ending balance	(5,740)		(10,075)		(5,740)	(10,075)
Foreign Currency Contracts
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(4,080)		1,194	(4,080)	1,194
Other comprehensive (loss) income before reclassification					2,265	(5,857)
Amounts reclassified out of AOCI					2,087	(673)
Tax effects					(743)	1,091
Total other comprehensive income (loss), net of tax					3,609	(5,439)
Ending balance	(471)		(4,245)		(471)	(4,245)
Total
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(12,453)	(11,656)	(8,917)	(7,005)	(11,656)	(7,005)
Total other comprehensive income (loss), net of tax	6,242	(797)	(5,403)	(1,912)
Ending balance	$ (6,211)	$ (12,453)	$ (14,320)	$ (8,917)	$ (6,211)	$ (14,320)

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2021	Aug. 31, 2020
Segment information
Sales revenue, net	$ 475,228	$ 530,852	$ 1,016,451	$ 951,687
Restructuring charges	369	34	375	367
Operating income	67,291	99,275	132,126	156,254
Capital and intangible asset expenditures	19,948	8,786	23,954	15,237
Depreciation and amortization	8,728	9,336	17,441	18,476
Housewares
Segment information
Sales revenue, net	215,218	201,863	408,862	342,491
Restructuring charges	369	25	369	263
Operating income	41,921	45,403	69,064	68,636
Capital and intangible asset expenditures	17,050	2,820	20,037	5,537
Depreciation and amortization	2,815	2,250	5,363	4,372
Health & Home
Segment information
Sales revenue, net	141,479	211,454	345,575	411,410
Restructuring charges	0	0	0	0
Operating income	4,794	33,771	16,043	65,304
Capital and intangible asset expenditures	2,232	4,497	2,980	7,905
Depreciation and amortization	2,624	4,173	5,350	8,225
Beauty
Segment information
Sales revenue, net	118,531	117,535	262,014	197,786
Restructuring charges	0	9	6	104
Operating income	20,576	20,101	47,019	22,314
Capital and intangible asset expenditures	666	1,469	937	1,795
Depreciation and amortization	$ 3,289	$ 2,913	$ 6,728	$ 5,879

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	May 31, 2020	Aug. 31, 2021	Aug. 31, 2020	Feb. 28, 2018
Income Tax Contingency [Line Items]
One time tax charge required due to Tax Act						$ 17,900,000
Income tax expense	$ 12,700,000	$ 9,257,000		$ 17,670,000	$ 2,340,000	$ 9,400,000
Income tax expense (benefit) as a percent of income before income taxes	19.80%	9.60%		14.00%	1.60%
U S tax liability for income generated in Macau	$ 0			$ 0
COVID-19
Income Tax Contingency [Line Items]
One-time income tax benefit, CARES Act			$ 9,400,000

Earnings per Share (Details)

Earnings per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2021	Aug. 31, 2020
Weighted average diluted securities
Weighted average shares outstanding, basic (in shares)	24,101	25,325	24,225	25,289
Incremental shares from share-based payment arrangements (in shares)	246	133	267	139
Weighted average shares outstanding, diluted (in shares)	24,347	25,458	24,492	25,428
Anti-dilutive securities
Weighted average diluted securities
Antidilutive securities (in shares)	29	180	15	221